Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerSuzanne L. Topalian, Mario Sznol, F. Stephen Hodi et al.|New England Journal of Medicine|2012Cited by 12.6k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAM.C. Liu, David R. Spigel, Alan H. Bryce et al.|Annals of Oncology|2020Cited by 1.5k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerScott Gettinger, Julie R. Brahmer, Leora Horn et al.|Journal of Clinical Oncology|2015Cited by 1.2k
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric‐Bernstam, John D. Hainsworth, Herbert I. Hurwitz et al.|The Lancet Oncology|2019Cited by 564
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung CancerJoachim von Pawel, Markus F. Renschler, Robert M. Jotte et al.|Journal of Clinical Oncology|2014Cited by 344